The ability of leucocytes
The ability of leucocytes to adhere to endothelium is essential for leucocyte migration into inflammatory sites. Some of these adhesion molecules are released from the cell surface and can be detected in serum. The soluble adhesion molecules intercellular adhesion molecule 1 (ICAM-1), E selectin, and vascular cell adhesion molecule 1 (VCAM-1) were studied in the serum of patients with Crohn's disease, ulcerative colitis, and healthy controls. A second blood sample was taken from patients with active disease after one month of treatment and a third two months after remission was achieved. Tissue expression of the same adhesion molecules was studied by immunohistology. Circulating VCAM-1 concentrations were significantly higher in patients with active ulcerative colitis (n=11, median= 165 U/ml) compared with patients with inactive ulcerative colitis (n=10, median= 117 U/ml, p<0.005), active Crohn's disease (n= 12, median= 124 U/ml, p<0.02), and controls (n=90, median=50 U/ml, p<OO001). Within each disease group there were no significant differences in E selectin or ICAM-1 concentrations between the active and inactive states, however, patients with active Crohn's disease had significantly higher ICAM-1 concentrations (n= 12, median=273 nglml) than controls (n=28, median=168, p<0O003). VCAM-1 concentrations fell significantly from pretreatment values to remission in active ulcerative colitis (p<0.01). In Crohn's disease there was a significant fall in ICAM-1 both during treatment (p<0.01) and two months after remission (p<0.02). Vascular Active disease -13 patients were treated with 30 mg prednisolone daily, three patients who relapsed while receiving corticosteroids were given azathioprine, another patient opted for treatment with a polymeric diet (Triosorbon, E Merck, Alton, Hampshire, UK), the other three had distal ulcerative colitis and received either 5-ASA or corticosteroid enemas, but one of these failed to respond and required oral prednisolone. Two patients with Crohn's disease and one with ulcerative colitis who relapsed while taking prednisolone were referred for surgery. Seven patients with active ulcerative colitis were taking aminosalicylates (maintenance dose) and these were continued in the same dose throughout the study.
Inactive disease -of the patients with inactive Crohn's disease, two were taking prednisolone (5 mg and 10 mg) and azathioprine, two azathioprine alone, two prednisolone alone (2-5 and 10 mg), and four were receiving no treatment. Three patients included in the inactive ulcerative colitis group were taking prednisolone (5, 7.5, and 10 mg) and aminosalicylates, three were taking aminosalicylates alone, and four patients were not taking any drugs.
Samples were also obtained from 90 healthy laboratory and clinical personnel and blood donors (age range 18-60) and assayed for E selectin and VCAM-1. In the case of ICAM-1, a subgroup of 27 of the control samples (age range 24-54) were assayed.
Endoscopic biopsy specimens or surgical sections of small or large bowel, or both, were taken from eight patients with Crohn's disease and nine patients with ulcerative colitis. These included biopsy specimens from six patients with active ulcerative colitis and two patients with active Crohn's disease who also had serum samples taken. Endoscopic biopsy specimens from eight patients undergoing colonoscopy for investigation of abdominal pain (in whom no abnormality was subsequently found) or sections from surgical specimens of patients with colonic carcinoma (obtained well away from the tumour area) and diverticular disease were used as normal controls. The following were also measured for each patient: haemoglobin, white cell and platelet ABC-HRP complex kit) according to the manufacturer's instructions followed by washing and incubation in DAB (diaminobenzidine). No cells in the lamina propria (other than endothelial cells) showed specific labelling for E selectin or VCAM-1. There was epithelial connective tissue labelling in a few cases. In these cases there was diffuse epithelial labelling present in an identical pattern with all three antibodies, which was considered to be nonspecific. In one case of active Crohn's disease, there was a distinct pattern of focal epithelial labelling with the ICAM antibody only, which may therefore be specific.
There The concentration of soluble ICAM-1 in patients with active Crohn's disease and VCAM-1 in patients with ulcerative colitis fell after corticosteroid treatment. Corticosteroids are known to affect ICAM-1 expression.44 Although, as stated previously, in the inactive disease group there was no significant difference between patients taking corticosteroids and those who were not. However, patients were receiving lower doses of corticosteroids than the active group. The reduction may result from down regulation of the release or expression of adhesion molecules, or both. By down regulating the expression of these molecules on endothelium, their interaction with immune cells will be reduced and inflammatory activity diminished. This mechanism of action may be of importance in inducing remission in inflammatory bowel disease.
Von Willebrand is increased as part of the acute phase response in humans45 and is increased in inflammatory bowel disease. 46 Stevens et al46 found, as we did, that serum von Willebrand activity was unrelated to disease activity in Crohn's disease but was significantly raised in active compared with inactive ulcerative colitis. They suggested that the increase is compatible with the proposal that vascular injury is an early event in the pathogenesis of Crohn's disease. 47 If circulating concentrations of adhesion molecules are a reflection of vascular inflammation, the increased concentrations of sICAM-1 in a few patients with inactive Crohn's disease would be compatible with continuing vascular inflammation in patients with inactive Crohn's disease.
It is possible that the positive correlation between sICAM-1 and the acute phase protein C reactive protein, and the negative correlation with the negative acute phase protein albumin reflects the activity of circulating cytokines. As previously discussed, cytokines such as ILI and TNFa, are important in upregulating expression of ICAM-1. These cytokines, together with IL6, can differentially regulate production of acute phase proteins.48
The reason why two of the healthy controls had VCAM concentrations of >1000 U/ml is unclear but probably does not result from assay interference as normal values of ICAM-1 and E selectin were detected in these samples using assays of a similar design. Similar concentrations of VCAM-1 were detected in repeat samples two months later.
The physiological importance of these soluble molecules is unclear; they may merely represent a spill over from the cell bound molecule, alternatively, they may regulate cell adhesion by competition as indeed, both sICAM-1 and sVCAM-1 can support leucocyte adhesion when immobilised to plastic.49
By binding to receptors on leucocytes, soluble adhesion molecules may prevent adherence of inflammatory cells to vascular endothelium and hence diminish inflammation. On the other hand, they may trigger a response in a ligand bearing cell.
In conclusion, raised circulating concentrations of selected adhesion molecules are associated with inflammatory bowel disease and are related to disease activity in ulcerative colitis. There is also evidence of local upregulation, particularly of ICAM-1. Differential expression of adhesion molecules in tissue may play a part in the initiation of leucocyte migration and local inflammation; it is possible that circulating forms play a protective part in inflammation by competing in cell to cell adhesion. Further studies are required to determine their role in the inflammatory process.
Some of these data have previously been published in abstract form (Gut 1993; 34 (suppl 1): S12).
